Printer Friendly

ONCOGENE SCIENCE ISSUED TWO PATENTS FOR RAS ONCOGENE

 ONCOGENE SCIENCE ISSUED TWO PATENTS FOR RAS ONCOGENE
 UNIONDALE, N.Y., March 16 /PRNewswire/ -- Oncogene Science, Inc.


(NASDAQ: ONCS), announced today that it has received two patents related to the ras oncogene.
 The first patent (No. 5,081,230) is entitled "Monoclonal antibodies reactive with the normal and oncogenic forms of the ras p21 protein" and the second patent (No. 5,084,380) is entitled "Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins." These ras patents describe monoclonal antibodies to the ras oncogene p21 that will be useful in developing clinical assays to diagnose, stage, and/or classify malignant and pre-malignant lesions.
 Ras oncogene mutations have been shown to be early events in the development of cancers of the colon, lung and pancreas. Recently published reports have shown the presence of these ras mutations in plasma samples and therefore the presence of these mutant ras proteins in blood samples may be valuable markers for the early detection of malignancy.
 These patents in conjunction with other issued patents, which broadly claim methods of detecting oncogenes and tumor suppressor genes, were acquired by Oncogene Science as part of the recent acquisition of the cancer business of Applied bioTechnology in Cambridge, Mass. Collectively, these patents represent a further strengthening of the company's overall intellectual property in oncogenes and tumor suppressor genes. The commercialization of this cancer diagnostics business is the goal of Oncogene Science's collaboration with Becton Dickinson & Co.
 Oncogene Science, Inc., using proprietary oncogene-related and growth factor technologies, is in the business of developing biopharmaceutical products for the research, diagnosis and treatment of cancer and other cell control-linked diseases.
 -0- 3/16/92
 /CONTACT: Robert L. Van Nostrand, vice president/finance and administration of Oncogene Science, 516-222-0023; or Susan Noonan or Anthony J. Russo of Noonan/Russo Communications, 212-979-9180, for Oncogene Science/
 (ONCS) CO: Oncogene Science, Inc. ST: New York, Massachusetts IN: MTC SU:


GK-SB -- NY019 -- 8165 03/16/92 09:26 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 16, 1992
Words:323
Previous Article:HEALTH CARE REFORM, CIVIL RIGHTS ACT TOP AGENDA AT SHRM 10TH ANNUAL LEGISLATIVE CONFERENCE
Next Article:EQUITABLE GAS TO FILE FOR RATE DECREASE
Topics:


Related Articles
ONCOGENE SCIENCE ISSUED PATENT FOR RAS ONCOGENE
ONCOGENE SCIENCE REPORTS THIRD QUARTER RESULTS
ONCOGENE SCIENCE, INC. REPORTS FIRST QUARTER RESULTS
ONCOGENE SCIENCE AND HOECHST ENTER COLLABORATIVE AGREEMENT
ONCOGENE SCIENCE ISSUED PATENT FOR RAS ONCOGENE
ONCOGENE SCIENCE, INC. RECEIVES BROAD U.S. PATENT COVERING ALL ANTIBODIES SPECIFIC FOR MUTANT RAS PROTEINS
ONCOGENE SCIENCE, INC. REPORTS WOUND HEALING DATA
ONCOGENE SCIENCE, INC. REPORTS START OF HUMAN CLINICAL TRIAL FOR WOUND HEALING
Oncogene Science and Hoechst Marion Roussel Form Collaboration To Develop Small Molecule Compounds to Treat Chronic Anemias
Walter P. Carney, Ph.D. is Elected Corporate Vice President of Oncogene Science

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters